Association of tumor necrosis factor-α-238G>A and apolipoprotein E2 polymorphisms with intracranial hemorrhage after brain arteriovenous malformation treatment

Neurosurgery

Volumn 61, Issue 4, 2007, Pages 731-739

  Achrol, Achal S ^a   Kim, Helen ^a   Pawlikowska, Ludmila ^b   Poon, K Y Trudy ^a   McCulloch, Charles E ^a   Ko, Nerissa U ^b   Johnston, S Claiborne ^b   McDermott, Michael W ^a   Zaroff, Jonathan G ^a   Lawton, Michael T ^a   Kwok, Pui Yan ^b   Young, William L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arteriovenous malformation; Cerebral hemorrhage; Genetic epidemiology; Microsurgical resection; Radiosurgery; Risk prediction

Indexed keywords

APOLIPOPROTEIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIOVENOUS MALFORMATION; ARTICLE; ARTIFICIAL EMBOLISM; BRAIN HEMORRHAGE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; PHENOTYPE; PRIORITY JOURNAL; RADIOSURGERY; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; APOLIPOPROTEIN E2; ARTERIOVENOUS MALFORMATIONS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VARIATION (GENETICS);

EID: 35948972450     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000298901.61849.A4     Document Type: Article

References (35)

1. Achrol AS, Pawlikowska L, McCulloch CE, Poon KYT, Ha C, Zaroff JG, Johnston SC, Lee C, Lawton MT, Sidney S, Marchuk D, Kwok P-Y, Young WL: Tumor necrosis factor-alpha-238G>A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke 37:231-234, 2006.
2. Biehle SJ, Carrozzella J, Shukla R, Popplewell J, Swann M, Freeman N, Clark JF: Apolipoprotein E isoprotein-specific interactions with tissue plasminogen activator. Biochim Biophys Acta 1689:244-251, 2004.
3. Bodles AM, Barger SW: Cytokines and the aging brain - What we don't know might help us. Trends Neurosci 27:621-626, 2004.
4. Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, Fagan SC, Kothari R, Levine SR, Marler JR, Lyden PD, Haley EC Jr., Brott T, Grotta JC: Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 49:736-744, 2001.
5. Bruunsgaard H, Pedersen M, Pedersen BK: Aging and proinflammatory cytokines. Curr Opin Hematol 8:131-136, 2001.
6. Chen Y, Fan Y, Poon KY, Achrol AS, Lawton MT, Zhu Y, McCulloch CE, Hashimoto T, Lee C, Barbaro NM, Bollen AW, Yang GY, Young WL: MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Front Biosci 11:3121-3128, 2006.
7. Chen Y, Pawlikowska L, Yao JS, Shen F, Zhai W, Achrol AS, Lawton MT, Kwok PY, Yang GY, Young WL: Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol 59:72-80, 2006.
8. Clark JF, Huri DA, Carrozzella J, Jauch EC, Mehta P, Heaton D, Biehle SJ, Broderick JP: Isoforms of apolipoprotein E can modulate tPA-induced clot lysis in vitro. Front Biosci 7:a163-168, 2002.
9. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC: Apolipoprotein E polymorphism and cardiovascular disease: AHuGE review. Am J Epidemiol 155:487-495, 2002.
10. Feuerstein GZ, Liu T, Barone FC: Cytokines, inflammation, and brain injury: Role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 6:341-360, 1994.
11. Fullerton HJ, Achrol AS, Johnston SC, McCulloch CE, Higashida RT, Lawton MT, Sidney S, Young WL: Long-term hemorrhage risk in children versus adults with brain arteriovenous malformations. Stroke 36:2099-2104, 2005.
12. Halim AX, Johnston SC, Singh V, McCulloch CE, Bennett JP, Achrol AS, Sidney S, Young WL: Longitudinal risk of intracranial hemorrhage in patients with arteriovenous malformation of the brain within a defined population. Stroke 35:1697-1702, 2004.
13. Halim AX, Singh V, Johnston SC, Higashida RT, Dowd CF, Halbach VV, Lawton MT, Gress DR, McCulloch CE, Young WL: Characteristics of brain arteriovenous malformations with coexisting aneurysms: A comparison of two referral centers. Stroke 33:675-679, 2002.
14. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695, 2005.
15. Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY, Barbaro NM, Higashida RT, Dowd CF, Halbach VV, Young WL: Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke 34:925-931, 2003.
16. Hsu TM, Kwok PY: Homogeneous primer extension assay with fluorescence polarization detection. Methods Mol Biol 212:177-187, 2003.
17. Joint Writing Group of the Technology Assessment Committee American Society of Interventional and Therapeutic Neuroradiology; Joint Section on Cerebrovascular Neurosurgery, a Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons; Section of Stroke and the Section of Interventional Neurology of the American Academy of Neurology: Reporting terminology for brain arteriovenous malformation clinical and radiographic features for use in clinical trials. Stroke 32:1430-1442, 2001.
18. Kim H, Sidney S, McCulloch CE, Poon KY, Singh V, Johnston SC, Ko NU, Achrol AS, Lawton MT, Higashida RT, Young WL: Racial/ethnic differences in longitudinal risk of intracranial hemorrhage in brain arteriovenous malformation patients (Abstract). Stroke 38:468, 2007.
19. Laskowitz DT, Goel S, Bennett ER, Matthew WD: Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 76:70-74, 1997.
20. Laskowitz DT, Horsburgh K, Roses AD: Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 18:465-471, 1998.
21. Lawton MT, Du R, Tran M, Achrol AS, McCulloch CE, Johnston SC, Quinnine NJ, Young WL: Effect of presenting hemorrhage on outcome after microsurgical resection of brain arteriovenous malformations. Neurosurgery 56:485-493, 2005.
22. Lee CK, Weindruch R, Prolla TA: Gene-expression profile of the ageing brain in mice. Nat Genet 25:294-297, 2000.
23. Leung CH, Poon WS, Yu LM, Wong GK, Ng HK: Apolipoprotein e genotype and outcome in aneurysmal subarachnoid hemorrhage. Stroke 33:548-552, 2002.
24. Lo EH, Dalkara T, Moskowitz MA: Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415, 2003.
25. Mast H, Young WL, Koennecke HC, Sciacca RR, Osipov A, Pile-Spellman J, Hacein-Bey L, Duong H, Stein BM, Mohr JP: Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation. Lancet 350:1065-1068, 1997.
26. Michikawa M, Fan QW, Isobe I, Yanagisawa K: Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74:1008-1016, 2000.
27. Pawlikowska L, Poon KY, Achrol AS, McCulloch CE, Ha C, Lum K, Zaroff JG, Ko NU, Johnston SC, Sidney S, Marchuk DA, Lawton MT, Kwok PY, Young WL: Apolipoprotein E epsilon 2 is associated with new hemorrhage risk in brain arteriovenous malformation. Neurosurgery 58:838-843, 2006.
28. Pawlikowska L, Tran MN, Achrol AS, McCulloch CE, Ha C, Lind DL, Hashimoto T, Zaroff J, Lawton MT, Marchuk DA, Kwok PY, Young WL; UCSF BAVM Study Project: Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke 35:2294-2300, 2004.
29. Reich K, Mössner R, König IR, Westphal G, Ziegler A, Neumann C: Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 118:155-163, 2002.
30. Saurwein-Teissl M, Blasko I, Zisterer K, Neuman B, Lang B, Grubeck-Loebenstein B: An imbalance between pro- and anti-inflammatory cytokines, a characteristic feature of old age. Cytokine 12:1160-1161, 2000.
31. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF: Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol 144:129-135, 1990.
32. Spetzler RF, Martin NA: A proposed grading system for arteriovenous malformations. J Neurosurg 65:476-483, 1986.
33. Stapf C, Mast H, Sciacca RR, Choi JH, Khaw AV, Connolly ES, Pile-Spellman J, Mohr JP: Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology 66:1350-1355, 2006.
34. Stapf C, Mohr JP, Choi JH, Hartmann A, Mast H: Invasive treatment of unruptured brain arteriovenous malformations is experimental therapy. Curr Opin Neurol 19:63-68, 2006.
35. Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA, Moomaw CJ, Fontaine RN, Broderick JP: Genetic and environmental risk factors for intracerebral hemorrhage: Preliminary results of a population-based study. Stroke 33:1190-1196, 2002.